CT-guided biopsies of unspecified suspect intrahepatic lesions: pre-procedure Lipiodol-marking improves the biopsy success rate
, , , , , und
21. Juni 2023
Über diesen Artikel
Artikel-Kategorie: Research Article
Online veröffentlicht: 21. Juni 2023
Seitenbereich: 158 - 167
Eingereicht: 17. Feb. 2023
Akzeptiert: 20. Apr. 2023
DOI: https://doi.org/10.2478/raon-2023-0024
Schlüsselwörter
© 2023 Marcel Christian Langenbach et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.

FIGURE 2.

FIGURE 3.

FIGURE 4.

Overview of patient characteristics_ P-values based on the Chi-square test indicate only a difference in the distribution of liver cirrhosis in comparison of the three enhancement groups
61.0 ± 12.0 | 61.9 ± 11.95 | 60.4 ± 11.12 | 59.6 ± 13.04 | 0.228 | |
0.134 | |||||
Male | 358 (59.0) | 177 (55.1) | 108 (74.5) | 73 (51.8) | |
Female | 249 (41.0) | 144 (44.9) | 37 (25.5) | 68 (48.2) | |
0.354 | |||||
HCV | 101 (16.6) | 34 (10.6) | 53 (36.6) | 14 (9.9) | |
HBV | 28 (4.6) | 6 (1.9) | 17 (11.7) | 5 (3.5) | |
HCV+HBV | 8 (1.3) | 3 (0.9) | 3 (2.1) | 2 (1.4) | |
NASH | 34 (5.6) | 12 (3.7) | 17 (11.7) | 5 (3.5) | |
Toxic damage | 48 (7.9) | 20 (6.2) | 16 (11.0) | 12 (8.5) | |
Others | 53 (8.7) | 26 (8.1) | 19 (13.1) | 8 (5.7) | |
No disease | 335 (55.2) | 220 (68.5) | 20 (13.8) | 95 (67.4) | |
188 (33.0) | 59 (19.2) | 100 (71.9) | 29 (3.6) | 0.013 | |
0.541 | |||||
1 lesion | 297 (48.9) | 164 (51.1) | 68 (46.9) | 65 (46.1) | |
2 lesions | 116 (19.1) | 45 (14.0) | 37 (25.5) | 34 (24.1) | |
3 or more lesions | 194 (32.0) | 112 (34.9) | 40 (27.6) | 42 (29.8) | |
29.3 ± 18.0 | 30.1 ± 18.1 | 25.9 ± 17.4 | 29.8 ± 18.7 | 0.182 |
Biopsy characteristics overall and for the three enhancement groups_ A Chi-square test was performed to test for differences between the groups_ Significance is indicated in bold
0.718 | |||||
Lateral-intercostal | 335 (55.2) | 162 (50.5) | 94 (64.8) | 79 (56.0) | |
Anterior-subcostal | 224 (36.9) | 25 (7.8) | 9 (6.2) | 10 (7.1) | |
Anterior-lateral | 44 (7.2) | 132 (41.1) | 42 (29.0) | 50 (35.5) | |
Dorsal-lateral | 4 (0.7) | 2 (0.6) | 0 | 2 (1.4) | |
0.052 | |||||
|
6 (1.0) | 2 (0.6) | 2 (1.4) | 2 (1.4) | |
2 | 54 (8.9) | 29 (9.0) | 14 (9.7) | 11 (7.8) | |
3 | 41 (6.8) | 23 (7.2) | 8 (5.5) | 10 (7.1) | |
4 | 112 (18.5) | 66 (20.6) | 23 (15.9) | 23 (16.3) | |
5 | 95 (15.7) | 57 (17.8) | 21 (14.5) | 17 (12.1) | |
6 | 112 (18.5) | 69 (21.5) | 21 (14.5) | 22 (15.6) | |
7 | 82 (13.5) | 31 (9.7) | 22 (15.2) | 29 (20.6) | |
8 | 105 (17.3) | 44 (13.7) | 34 (23.4) | 27 (19.1) | |
Cutis to lesion | 83 ±26 | 82 ±27 | 85 ±27 | 83 ±26 | 0.527 |
Liver capsule to lesion | 43 ±26 | 44 ±21 | 41 ±21 | 43 ±21 | 0.473 |
2.6 ±1.3 | 2.7 ±1.5 | 2.5 ±0.9 | 2.4 ±0.9 | 0.158 | |
Whole examination [mGycm2] | 498.3 ±429.5 | 361.0 ±166.6 | 411.3 ±517.9 | 900.3 ±495.6 | |
Biopsy scans [mGycm2] | 80.1 ±58.0 | 79.7 ±60.0 | 88.2 ±56.3 | 72.6 ±56.4 | 0.053 |
Intervention |
34.4 ±24.0 | 34.6 ±23.8 | 37.7 ±23.4 | 30.6 ±24.7 | 0.182 |
0.870 | |||||
Sub-capsular liver bleeding | 3 (0.5) | 1 (0.3) | 1 (0.7) | 1 (0.7) | |
Fluid edge around liver | 2 (0.3) | 1 (0.3) | 0 | 1 (0.7) | |
Bleeding along the access path | 1 (0.2) | 0 | 1 (0.7) | 0 | |
Circulatory problems | 1 (0.2) | 1 (0.3) | 0 | 0 |